- Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously.
Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2016-12-21)
Falk Saupe, Matthias Reichel, Elisabeth J M Huijbers, Julia Femel, Per-Olof Markgren, C Evalena Andersson, Sebastian Deindl, U Helena Danielson, Lars T Hellman, Anna-Karin Olsson
PMID27993994
ABSTRAKT
With the aim to improve the efficacy of therapeutic vaccines that target self-antigens, we have developed a novel fusion protein vaccine on the basis of the C-terminal multimerizing end of the variable lymphocyte receptor B (VLRB), the Ig equivalent in jawless fishes. Recombinant vaccines were produced in
MATERIAŁY
Numer produktu
Marka
Opis produktu
Sigma-Aldrich
3,3′,5,5′-Tetramethylbenzidine (TMB) Liquid Substrate System, peroxidase substrate
Informacje o cenach i dostępności nie są obecnie dostępne.